This study presents the experience of one year of treatment in patients with 
amyotrophic lateral sclerosis, with intrathecal TRH administered daily by a 
subcutaneous reservoir connected to the intrathecal lumbar space by a double 
catheter system as to provide continuous circulation of CSF and to avoid sac 
formation since this would be a source of infection. Clinical evaluation was 
carried out with a scale developed by the authors with the main aim of 
evaluating the loss of vital motor abilities and not as a localized evaluation. 
Secondary effects due to the implantation of the reservoir in addition to its 
use are presented although data were not important. Intrathecal administration 
of TRH was carried out similarly (600 micrograms/day) with secondary effects 
being the same as those by other routes of administration although of a lesser 
intensity. The results of the clinical evaluation at the beginning and end of 
the treatment as well as after patient follow up demonstrated that beneficial 
effects do not occur equally in all patients but rather are transitory and do 
not improve the natural evolution of the disease. The authors conclude that, 
methodologically, this series study does not enter within the frame of an 
advisable statistical study since the aim is to provide data for a future 
controlled study.